Liu 2009.

Methods	Allocation: randomised, no further details. Blindness: unclear. Duration: eight weeks. Design: parallel. Setting: inpatient and outpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 68. Age: aripiprazole group: mean = (26.1 ± 7.5) years; olanzapine group: mean = (27.4 ± 8.4) years. Gender: aripiprazole group: 18 male, 16 female; olanzapine group: 17 male, 17 female. History: aripiprazole group: mean = (6.9 ± 3.4) years; olanzapine group: mean = (6.5 ± 3.6) years. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 10‐30 mg/day. Mean = (19.7 ± 5.3) mg/day. N = 34. 2. Olanzapine: Dose range: 10‐20 mg/day. Mean = (15.4 ± 4.5) mg/day. N = 34.
Outcomes	Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score, PANSS psychopathological subscale score. Quality of life: GQOLI‐ 74 total score, GQOLI‐ 74 material life score, GQOLI‐ 74 physical health score, GQOLI‐ 74 mental health score, GQOLI‐ 74 social function score. Adverse effects.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not reported.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Unclear if there were incomplete data.
Selective reporting (reporting bias)	High risk	Data on TESS total score, use of benzodiazepines and benzhexol were missing.
Other bias	Low risk	None obvious.